Guest Editors: D. Efremov and L. Laurenti

TOLL-LIKE RECEPTORS IN CHRONIC LYMPHOCYTIC LEUKEMIA Marta Muzio, Eleonora Fonte, Federico Caligaris-Cappio | DOI: 10.4084/mjhid.2012.055e2012055REGULATORY T-CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA Giovanni D'arena, Giovanni Rossi, Barbara Vannata, Silvia Deaglio | DOI: 10.4084/mjhid.2012.053e2012053THE SPECTRUM OF GENETIC DEFECTS IN CHRONIC LYMPHOCYTIC LEUKEMIA Davide Rossi, Marco Fangazio, Gianluca Gaidano | DOI: 10.4084/mjhid.2012.076e2011076IMMUNOGLOBULIN GENE REPERTOIRE IN CHRONIC LYMPHOCYTIC LEUKEMIA: INSIGHT INTO ANTIGEN SELECTION AND MICROENVIRONMENTAL INTERACTIONS Efterpi Kostareli, Maria Gounari, Andreas Agathangelidis, Kostas Stamatopoulos | DOI: 10.4084/mjhid.2012.052e2012052NOVEL AGENTS AND EMERGING STRATEGIES FOR TARGETING THE B-CELL RECEPTOR PATHWAY IN CLL Dimitar Efremov, Adrian Wiestner, Luca Laurenti | DOI: 10.4084/mjhid.2012.067e2012067INFECTIOUS COMPLICATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA AnnaMaria Nosari | DOI: 10.4084/mjhid.2012.070e2012070

“IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.”

Sara Martinelli, Antonio Cuneo, Gian Matteo Rigolin

DOI: 10.4084/mjhid.2016.047

 

PDF

 

HTML

 

e2016047

BCR SIGNALING INHIBITORS: AN OVERVIEW OF TOXICITIES ASSOCIATED WITH IBRUTINIB AND IDELALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

Lorenzo Falchi, Jessica M Baron, Carrie Anne Orlikowski, Alessandra Ferrajoli

DOI: 10.4084/mjhid.2016.011

 

PDF

 

HTML

 

e2016011